The Negative Expression of Annexin A1 in Esophageal Squamous Cell Carcinoma is Associated with Poor Outcome
X. Huang,Q. Wang,T. Li,F. Li,J. Lang
DOI: https://doi.org/10.1016/j.ijrobp.2013.06.755
2013-01-01
Abstract:Annexin A1 (ANXA1) is a calcium-binding protein involved in arachidonic acid metabolism and epidermal growth factor receptor tyrosine kinase pathway. ANXA1 has been implicated in early squamous cell carcinogenesis of esophagus and correlates with degree of tumor differentiation. Our goal was to evaluate ANXA1 expression its correlation with different chemoradiation therapy (CRT) sensitivity and determine its prognostic significance in esophageal squamous cell carcinoma (ESCC). Immunohistochemical staining was used to assay the expression of ANXA1 in 60 patients (14 stage II, 6 stage III, and 40 stage IV) who underwent concurrent CRT from August 2007 to June 2011, and the clinical stage was determined according to the International Union against Cancer (UICC) Tumor-node-metastasis (TNM) 2002 classification. ANAX1 expression level was classified as positive (≥5% of tumor cells with cytoplasmic staining), negative (<5% of tumor cells with cytoplasmic staining), or negative; and was correlated with clinicopathologic features and patients' outcomes. The tissues were classified into responders group (completely remission, CR) and non- responders group (stable disease, SD) by endoscopy, according to the WHO Response Evaluation Criteria in Solid Tumors. The total positive expression rates of ANX A1 was 55.0% (33 of 60). Sixty patients were evaluable for response. There were 11 (18.4%) complete remission, 20 (33.3%) partial remission, 20 (33.3%) stable disease, and 9 (15.0%) progression disease. the positive expression rate of ANX A1 in responders was 72.7% (8 of 11), while 45.0% (9 of 20) in non-responders (p > 0.05). The expression of ANX A1 was not significantly correlated with patients’ age, gender, tumor location, tumor differentiation grade, T stage, N stage and clinical TNM stage (p > 0.05). In univariate analysis, overall survival correlated significantly with tumor differentiation grade (p = 0.004), short-term effect (p < 0.001, TNM stage (p = 0.039), Karnofsky performance status (p = 0.001) and ANXA1 expression (p = 0.050). Subgroup analysis for patients with stage IV, Patient with negative ANX A1 (n = 19) had significantly shorter median survival times than those with positive ANXA1 (n = 21) (11.4 months vs 13.1 months, p = 0.039). Our results indicate that positive ANXA1 expression is frequent in esophageal squamous cell carcinoma. The expression of ANX A1 was not associated with chemoradiation therapy sensitivity. However, it maybe serves as a novel prognostic biomarker for ESCC.